Steven Bloom

Steven Bloom


  • Senior Executive with 35 years of experience in the life sciences industry leading teams in corporate development, commercial planning, corporate affairs, and strategic consulting.

Corporate Development; Commercial Strategy and Planning; Corporate Affairs; Corporate / Department / Project Strategic Consulting, Planning, and Support; Business Development / Fundraising; Public Offerings; Long-term Financing; KOL Development; Brand Strategy; Reimbursement Planning; In-licensing; IR / PR Planning; Corporate Footprints (Commercial / Medical / Distribution); Corporate Branding / Rebranding and Positioning; Company Liaison / Advocate; Social Media Program Planning for Patient Enrollment; Medical / Corporate Communications and Marketing Planning; and Deal Models.
Chief Business Officer, Vavotar Life Sciences
As part of executive leadership team, deliver corporate strategy, business development, and KOL development services to biotechnology company developing a novel oncology-focused antibody drug conjugate (ADC) platform. Currently leading Series A fundraising initiative and long-term financing plan, and corporate branding and positioning initiatives.
Principal, SHB Consulting (SHBC)
Support emerging biotechnology companies with corporate strategy, fundraising, KOL eco-system development, and business development. Clients include Vigeo Therapeutics, Vavotar Life Sciences, Aura Biosciences, Samus Therapeutics, Synterus Therapeutics, and Solasia.
Chief Strategy Officer, Verastem Oncology
Executive Leadership Team member focused on developing and executing new corporate strategy for biotechnology company developing novel drugs targeting the tumor microenvironment. Responsible for corporate development, including in-licensing, business strategy, and IR/PR planning, and led the deal team that acquired duvelisib from Infinity Pharma in November 2016. Oversaw building commercial and medical affairs organizations prior to NDA filing in February 2018 and led crucial initiative to develop relationships with key global KOLs. Built EU footprint, including commercial, medical, and distribution. Interfaced with key orphan cancer patient advocacy groups and external organizations, key trade organizations, and government officials. Led the corporate re-branding campaign and Care Differently customer and stakeholder strategy. Provided strategic support for clinical operations team during execution phase of global rare cancer mesothelioma study and initiated social media programs focused on increasing patient enrollment.
Senior Vice President, Commercial Planning and Business Development, Ziopharm Oncology
Led the development of a global commercial strategy for lead program in sarcoma, including brand strategy and reimbursement plan. Developed and executed global business development plan that resulted in worldwide licensing deal with Japanese-based biotechnology company. Built a world-class rare cancer patient advocacy network to help support potential launch of products in lymphoma and sarcoma and was part of executive team during two successful public offerings (~ $85M).
Global Vice President, Business Development and Marketing, Parexel
Led reorganization of medical communications team of this biopharmaceutical services company providing clinical research, clinical logistics, and medical communications consulting to pharmaceutical and biotechnology companies. Built an account management-based infrastructure, created brand marketing plan for Medcom services offering, and helmed a six-person team to develop and implement new deal models and access “white space” opportunities in new therapeutic areas.
Vice President, Business Development, Pharmetrics 
Executive responsible for 75% of top line revenues for this provider of business intelligence and data solutions for pharmaceutical and biotechnology companies. Delivered year over year growth via a ten-person business development team. Drove successful integration of BD team into IMS infrastructure. Key member of executive team that positioned company for successful acquisition by IMS Health.

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.